胃食道逆流症治療薬の世界市場レポート 2025年

胃食道逆流症治療薬の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.5％で78億9,000万米ドルに成長します。予測期間の成長は、新規治療に対する需要の増加、高齢者人口の増加、個別化医療へのアプローチ、非薬理学的介入への注目、生物製剤や革新的治療法の出現などに起因すると考えられます。予測期間の主な動向には、代替療法や心身医学の実践、腸の健康に関する調査の拡大、患者中心のケアモデルの登場、ガードの啓発のためのターゲットマーケティング、デジタルヘルスツールの統合などが含まれます。

胃食道逆流症治療薬市場の予想成長率は、胃食道逆流症の流行によって牽引されると予想されます。この慢性疾患は、胃酸の食道への逆流を特徴とし、胸やけや逆流などの症状を引き起こします。胃食道逆流症（GERD）治療薬は、腸内pHを中和し、炎症を制御し、食道機能を改善することによって、これらの症状を軽減し、管理するようにデザインされています。例えば、2022年9月のWebMedの記事では、6,000万人以上のアメリカ人成人が少なくとも月に一度は胸焼けを経験し、1,500万人以上が毎日症状を経験していると報告されています。さらに、国立医学図書館は2022年7月、米国におけるGERDの有病率が20％と高く、経済的負担が大きく、生活の質にも影響を及ぼしていることを示す統計を発表しました。したがって、胃食道逆流症の有病率の増加は、治療薬市場の成長を促進すると予想されます。

セルフメディケーションの導入は、胃食道逆流症治療薬市場の継続的成長に重要な役割を果たしています。セルフメディケーションとは、ヘルスケア専門家に相談せずに薬物や物質を使用して病状を治療することです。この習慣は、誘因となる食品の特定と管理、ストレスへの対処、禁煙など、GERD症状の改善に寄与するすべてにおいて、個人にとって有益です。Lippincott Williams &Wilkins社が2022年5月に実施した調査によると、170人の参加者のうち57.7％がセルフメディケーションを実践しており、34.7％は医療従事者に相談する必要性を感じていませんでした。したがって、セルフメディケーションの普及が胃食道逆流症治療薬市場の牽引役となることが予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の胃食道逆流症治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の胃食道逆流症治療薬市場：成長率分析
• 世界の胃食道逆流症治療薬市場の実績：規模と成長, 2019-2024
• 世界の胃食道逆流症治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界の胃食道逆流症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の胃食道逆流症治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブランド
• ジェネリック
• 世界の胃食道逆流症治療薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 制酸剤
• プロトンポンプ阻害剤
• ヒスタミン遮断薬
• 運動促進剤
• その他の薬物クラス
• 世界の胃食道逆流症治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• ドラッグストア
• 雑貨店
• スーパーマーケット
• 世界の胃食道逆流症治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クローン病
• 胃食道逆流症（GERD）
• 潰瘍性大腸炎
• 世界の胃食道逆流症治療薬市場、タイプ別サブセグメンテーション：ブランド、実績と予測, 2019-2024, 2024-2029F, 2034F
• プロトンポンプ阻害剤（PPI）
• H2受容体拮抗薬
• 制酸剤
• コーティング剤
• 世界の胃食道逆流症治療薬市場、タイプ別サブセグメンテーション：ジェネリック、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジェネリックプロトンポンプ阻害剤（PPI）
• ジェネリックH2受容体拮抗薬
• ジェネリック制酸剤
• 汎用コーティング剤

第7章 地域別・国別分析

• 世界の胃食道逆流症治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の胃食道逆流症治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 胃食道逆流症治療薬市場：競合情勢
• 胃食道逆流症治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Medtronic PLC
• GlaxoSmithKline plc
• Eisai Co. Ltd.
• Takeda Pharmaceutical Company Limited
• bioMerieux SA
• Teva Pharmaceutical Industries
• Dr. Reddy's Laboratories Ltd.
• Amneal Pharmaceuticals LLC
• CHEPLAPHARM Arzneimittel GmbH
• Daewoong Pharmaceutical Co. Ltd
• Ironwood Pharmaceuticals Inc.
• Sebela Pharmaceuticals Inc.
• Camber Pharmaceuticals Inc.
• Sun Pharmaceutical Industries Ltd.
• EndoGastric Solutions

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 胃食道逆流症治療薬市場2029：新たな機会を提供する国
• 胃食道逆流症治療薬市場2029：新たな機会を提供するセグメント
• 胃食道逆流症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Gastroesophageal reflux disease (GERD) therapeutics encompass medications designed for the chronic medical condition characterized by the upward movement of stomach contents into the esophagus, leading to symptoms such as heartburn and regurgitation. These therapeutics aim to neutralize and diminish the production of stomach acid, maintaining an optimal pH level in the gut and preventing the backflow of fluids into the stomach that causes acid reflux.

The primary categories of gastroesophageal reflux disease therapeutics include branded and generic medications. Branded medications are those that can only be dispensed with a prescription from a physician or other authorized prescriber, adhering to state or federal regulations. These drugs are employed for the treatment of gastroesophageal reflux disease, aiming to alleviate symptoms and facilitate esophageal healing. Various drug classes, such as antacids, proton pump inhibitors, histamine blockers, pro-kinetic agents, among others, are distributed through diverse channels, including hospital pharmacies, drug stores, general stores, and supermarkets. These therapeutics find applications in conditions such as Crohn's disease, gastroesophageal reflux disease (GERD), and ulcerative colitis.

The gastroesophageal reflux disease therapeutics market research report is one of a series of new reports from The Business Research Company that provides gastroesophageal reflux disease therapeutics market statistics, including gastroesophageal reflux disease therapeutics industry global market size, regional shares, competitors with a gastroesophageal reflux disease therapeutics market share, detailed gastroesophageal reflux disease therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the gastroesophageal reflux disease therapeutics industry. This gastroesophageal reflux disease therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastroesophageal reflux disease therapeutics market size has grown steadily in recent years. It will grow from $5.93 billion in 2024 to $6.14 billion in 2025 at a compound annual growth rate (CAGR) of 3.6%. The growth in the historic period can be attributed to changing lifestyles and dietary habits, aging population, increased awareness and diagnosis, prevailing stressful lifestyles, rise in obesity rates

The gastroesophageal reflux disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $7.89 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to rise in demand for novel therapies, growing geriatric population, personalized medicine approaches, focus on non-pharmacological interventions, emergence of biologics and innovative therapies. Major trends in the forecast period include alternative therapies and mind-body practices, expanded research into gut health, advent of patient-centric care models, targeted marketing for gerd awareness, integration of digital health tools.

The anticipated growth in the gastroesophageal reflux disease therapeutics market is expected to be driven by the prevalence of gastroesophageal reflux disease. This chronic condition, characterized by the backflow of stomach acid into the esophagus, leads to symptoms such as heartburn and regurgitation. Gastroesophageal reflux disease (GERD) therapeutics are designed to reduce and manage these symptoms by neutralizing gut pH, controlling inflammation, and improving esophageal function. For example, a WebMed article in September 2022 reported that over 60 million American adults experience heartburn at least once a month, with more than 15 million experiencing daily symptoms. Additionally, the National Library of Medicine shared statistics in July 2022 indicating GERD's high prevalence of 20% in the United States, causing a significant economic burden and impacting quality of life. Hence, the increasing prevalence of gastroesophageal reflux disease is expected to fuel the growth of the therapeutics market.

The adoption of self-medication is playing a significant role in the continued growth of the gastroesophageal reflux disease therapeutics market. Self-medication involves using drugs or substances to treat a medical condition without consulting a healthcare professional. This practice is beneficial for individuals in identifying and managing trigger foods, handling stress, and quitting smoking, all of which contribute to improving GERD symptoms. A survey conducted in May 2022 by Lippincott Williams & Wilkins, involving 170 participants, revealed that 57.7% practiced self-medication, and 34.7% felt no need to consult a medical practitioner. Therefore, the adoption of self-medication is expected to be a driving factor in the gastroesophageal reflux disease therapeutics market.

Product innovations are a key trend gaining traction in the gastroesophageal reflux disease (GERD) therapeutics market. Major companies in this sector are concentrating on developing innovative medications to maintain their competitive edge. For instance, in November 2023, Phathom Pharmaceuticals, a US-based biopharmaceutical company, launched VOQUEZNA (vonoprazan), a potassium-competitive acid blocker approved for the healing and maintenance of all grades of erosive esophagitis, as well as for alleviating heartburn associated with both erosive and non-erosive GERD. Clinical trials demonstrated impressive results, with a healing rate of 93% in patients treated with the 20 mg dosage, compared to 85% for the standard proton pump inhibitor (PPI) lansoprazole. This innovation highlights the ongoing commitment to advancing treatment options in the GERD market.

Major companies in the gastroesophageal reflux disease therapeutics market are directing their efforts toward the development of innovative systems, including wireless pH-capsule reflux testing systems. These medical devices are specifically designed for diagnosing and monitoring gastroesophageal reflux disease (GERD) and related conditions. For instance, in April 2023, Laborie Medical Technologies Corp., a U.S.-based medical testing equipment manufacturer, introduced the alpHaONE system, a wireless pH-capsule reflux testing system tailored for GERD diagnosis. Offering up to 96 hours of data monitoring, this system ensures accurate and reliable data. The alpHaONE system features an ergonomic and compact design, user-friendly enlarged buttons, and a fail-safe capsule delivery system designed to protect the patient's esophagus.

In October 2022, Evonik Industries AG, a Germany-based specialty chemicals company, entered into a partnership with Phathom Pharmaceuticals. This collaboration aims to enable Evonik to produce large-scale volumes of vonoprazan at its FDA-inspected manufacturing sites in the United States and Germany. Phathom Pharmaceuticals, a U.S.-based biopharmaceutical company, is dedicated to developing innovative medicines for stomach acid-related disorders, including drugs for gastroesophageal reflux disease.

Major companies operating in the gastroesophageal reflux disease therapeutics market include Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic PLC, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, bioMerieux SA, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., EndoGastric Solutions, RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited

North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gastroesophageal reflux disease therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastroesophageal reflux disease (GERD) therapeutics market consists of sales of amino-salicylates (5-ASA), corticosteroids, immunomodulators, antibiotics, biologics, and dopamine receptor antagonist. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastroesophageal Reflux Disease Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastroesophageal reflux disease therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastroesophageal reflux disease therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastroesophageal reflux disease therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Branded; Generic
• 2) By Drug Class: Antacids; Proton Pump Inhibitors; Histamine Blockers; Pro-Kinetic Agents; Other Drugs Class
• 3) By Distribution Channel: Hospital Pharmacy; Drug Stores; General Stores; Supermarkets
• 4) By Application: Crohn's Disease; Gastroesophageal Reflux Disease (GERD); Ulcerative Colitis
• Subsegments:
• 1) By Branded: Proton Pump Inhibitors (PPIs); H2-Receptor Antagonists; Antacids; Coating Agents
• 2) By Generic: Generic Proton Pump Inhibitors (PPIs); Generic H2-Receptor Antagonists; Generic Antacids; Generic Coating Agents
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson; Novartis AG; Sanofi S.A.; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gastroesophageal Reflux Disease Therapeutics Market Characteristics

3. Gastroesophageal Reflux Disease Therapeutics Market Trends And Strategies

4. Gastroesophageal Reflux Disease Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Gastroesophageal Reflux Disease Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gastroesophageal Reflux Disease Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gastroesophageal Reflux Disease Therapeutics Market Growth Rate Analysis
• 5.4. Global Gastroesophageal Reflux Disease Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gastroesophageal Reflux Disease Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gastroesophageal Reflux Disease Therapeutics Total Addressable Market (TAM)

6. Gastroesophageal Reflux Disease Therapeutics Market Segmentation

• 6.1. Global Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Branded
• Generic
• 6.2. Global Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antacids
• Proton Pump Inhibitors
• Histamine Blockers
• Pro-Kinetic Agents
• Other Drug Classes
• 6.3. Global Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Drug Stores
• General Stores
• Supermarkets
• 6.4. Global Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Crohn's Disease
• Gastroesophageal Reflux Disease (GERD)
• Ulcerative Colitis
• 6.5. Global Gastroesophageal Reflux Disease Therapeutics Market, Sub-Segmentation Of Branded, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Proton Pump Inhibitors (PPIs)
• H2-Receptor Antagonists
• Antacids
• Coating Agents
• 6.6. Global Gastroesophageal Reflux Disease Therapeutics Market, Sub-Segmentation Of Generic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic Proton Pump Inhibitors (PPIs)
• Generic H2-Receptor Antagonists
• Generic Antacids
• Generic Coating Agents

7. Gastroesophageal Reflux Disease Therapeutics Market Regional And Country Analysis

• 7.1. Global Gastroesophageal Reflux Disease Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gastroesophageal Reflux Disease Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market

• 8.1. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gastroesophageal Reflux Disease Therapeutics Market

• 9.1. China Gastroesophageal Reflux Disease Therapeutics Market Overview
• 9.2. China Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gastroesophageal Reflux Disease Therapeutics Market

• 10.1. India Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gastroesophageal Reflux Disease Therapeutics Market

• 11.1. Japan Gastroesophageal Reflux Disease Therapeutics Market Overview
• 11.2. Japan Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gastroesophageal Reflux Disease Therapeutics Market

• 12.1. Australia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gastroesophageal Reflux Disease Therapeutics Market

• 13.1. Indonesia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gastroesophageal Reflux Disease Therapeutics Market

• 14.1. South Korea Gastroesophageal Reflux Disease Therapeutics Market Overview
• 14.2. South Korea Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gastroesophageal Reflux Disease Therapeutics Market

• 15.1. Western Europe Gastroesophageal Reflux Disease Therapeutics Market Overview
• 15.2. Western Europe Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gastroesophageal Reflux Disease Therapeutics Market

• 16.1. UK Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gastroesophageal Reflux Disease Therapeutics Market

• 17.1. Germany Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gastroesophageal Reflux Disease Therapeutics Market

• 18.1. France Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gastroesophageal Reflux Disease Therapeutics Market

• 19.1. Italy Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gastroesophageal Reflux Disease Therapeutics Market

• 20.1. Spain Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gastroesophageal Reflux Disease Therapeutics Market

• 21.1. Eastern Europe Gastroesophageal Reflux Disease Therapeutics Market Overview
• 21.2. Eastern Europe Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gastroesophageal Reflux Disease Therapeutics Market

• 22.1. Russia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gastroesophageal Reflux Disease Therapeutics Market

• 23.1. North America Gastroesophageal Reflux Disease Therapeutics Market Overview
• 23.2. North America Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gastroesophageal Reflux Disease Therapeutics Market

• 24.1. USA Gastroesophageal Reflux Disease Therapeutics Market Overview
• 24.2. USA Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gastroesophageal Reflux Disease Therapeutics Market

• 25.1. Canada Gastroesophageal Reflux Disease Therapeutics Market Overview
• 25.2. Canada Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gastroesophageal Reflux Disease Therapeutics Market

• 26.1. South America Gastroesophageal Reflux Disease Therapeutics Market Overview
• 26.2. South America Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gastroesophageal Reflux Disease Therapeutics Market

• 27.1. Brazil Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gastroesophageal Reflux Disease Therapeutics Market

• 28.1. Middle East Gastroesophageal Reflux Disease Therapeutics Market Overview
• 28.2. Middle East Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gastroesophageal Reflux Disease Therapeutics Market

• 29.1. Africa Gastroesophageal Reflux Disease Therapeutics Market Overview
• 29.2. Africa Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gastroesophageal Reflux Disease Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Gastroesophageal Reflux Disease Therapeutics Market Competitive Landscape
• 30.2. Gastroesophageal Reflux Disease Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Gastroesophageal Reflux Disease Therapeutics Market Other Major And Innovative Companies

• 31.1. Medtronic PLC
• 31.2. GlaxoSmithKline plc
• 31.3. Eisai Co. Ltd.
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. bioMerieux SA
• 31.6. Teva Pharmaceutical Industries
• 31.7. Dr. Reddy's Laboratories Ltd.
• 31.8. Amneal Pharmaceuticals LLC
• 31.9. CHEPLAPHARM Arzneimittel GmbH
• 31.10. Daewoong Pharmaceutical Co. Ltd
• 31.11. Ironwood Pharmaceuticals Inc.
• 31.12. Sebela Pharmaceuticals Inc.
• 31.13. Camber Pharmaceuticals Inc.
• 31.14. Sun Pharmaceutical Industries Ltd.
• 31.15. EndoGastric Solutions

32. Global Gastroesophageal Reflux Disease Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastroesophageal Reflux Disease Therapeutics Market

34. Recent Developments In The Gastroesophageal Reflux Disease Therapeutics Market

35. Gastroesophageal Reflux Disease Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Gastroesophageal Reflux Disease Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gastroesophageal Reflux Disease Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gastroesophageal Reflux Disease Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer